Finding the molecules to fuel chemogenomics

Drug Discovery Today: TARGETS

Volumn 1, Issue 4, 2002, Pages 125-129

  Namchuk, Mark N ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DIMETHYL SULFOXIDE; LOSARTAN; SEROTONIN ANTAGONIST;

BACTERIAL GROWTH; BIOLOGICAL ACTIVITY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG DESIGN; DRUG EFFECT; DRUG INDUSTRY; DRUG POTENCY; DRUG PURIFICATION; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG TARGETING; FLUORESCENCE ANALYSIS; FOLLOW UP; GENOME ANALYSIS; HUMAN; IN VITRO STUDY; INFORMATION PROCESSING; LIGAND BINDING; NONHUMAN; QUALITY CONTROL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; REVIEW; SCREENING TEST; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; TECHNIQUE; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

EID: 0037598287     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1477-3627(02)02206-7     Document Type: Review

References (22)

1. Caron, P. et al. (2001) Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 5, 464-470
2. Murcko, M. and Caron, P. (2002) Transforming the genome to drug discovery. Drug Discov. Today 7, 583-584
3. Zanders, E.D. et al. (2002) Probes for chemical genomics by design. Drug Discov. Today 7, 711-718
4. Stockwell, B. (2000) Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1, 116-125
5. Specht, K. and Shokat, K. (2002) The emerging power of chemical genetics. Curr. Opin. Cell Biol. 14, 155-159
6. Chan, T.F. et al. (2000) A chemical genomic approach towards understanding the global functions of the target of rapamycin protein (TOR). Proc. Natl Acad. Sci. U. S. A. 97, 13227-13232
7. Bishop, A.C. et al. (2001) Magic bullets for protein kinases. Trends Cell Biol. 11, 167-172
8. Lenz, A. et al. (2000) Chemical ligands, genomics and drug discovery. Drug Discov. Today 5, 145-156
9. MacBeath, G. (2001) Chemical genomics: what it will take and who gets to play? Genome Biol. 2, 2005
10. Zheng, X.F. and Chan, T-F. (2002) Chemical genomics in the global study of protein function. Drug Discov. Today 7, 197-205
11. Tao, J. et al. (2000) Drug target validation: lethal infection blocked by inducible peptide. Proc. Natl Acad. Sci. U. S. A. 97, 783-786
12. Aliamo, A. et al. (2001) Chemical genetic approaches for the elucidation of signalling path ways. Curr. Opin. Chem. Biol. 5, 360-367
13. Agrafiotis, A. et al. (2002) Combinatorial informatics in the post genomic era. Nat. Rev. Drug Discov. 1, 337-346
14. Pantoliano, A. et al. (2001 ) High-density thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429-440
15. Schuffenhauer, A. et al. (2002) An ontology of pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci. 42, 947-955
16. Davies, S.P. et al. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
17. Spencer, R. (1998) High-throughput screening of historical collections: observations on file size, biological targets and file density. Biotechnol. Bioeng. 61, 61-67
18. Landro, J.A. et al. (2000) HTS in the new millennium. The role of pharmacology and flexibility. J. Pharmacol. Toxicol. Methods 44, 273-289
19. McGovern, S. et al. (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712-1722
20. Neurogen has described a similar process for rapid assessment of receptor pharamacology, high-throughput pharmacology. Manly, C. "Connecting virtual library design and screening: Informatics in the prioritization of synthesis and screening in integrated high throughput drug discovery." Screentech 2001, March 12, 2001 San Deigo, CA.
21. Walters, W.P. et al. (1998) Virtual screening - an overview. Drug Discov. Today 3, 160-178
22. Walters, W.P. et al. (1999) Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 3, 384-387